ADC Therapeutics, an oncology drug discovery and development company that specializes in antibody drug conjugates (ADCs), and Adagene Inc., an antibody engineering and discovery company, have entered into a discovery collaboration and license agreement. ADC Therapeutics will use Adagene’s SAFEbody technology to generate a masked antibody that will be combined with ADC Therapeutics’ pyrrolobenzodiazepine  (PBD) cytotoxic payload technology for the development of a novel ADC against a solid tumor ...